Results 31 to 40 of about 1,110,820 (300)

Participant Perceptions in a Long-term Clinical Trial of Autosomal Dominant Polycystic Kidney Disease

Kidney Medicine, 2023
Rationale & Objective: The development of new therapies for autosomal dominant polycystic kidney disease requires clinical trials to be conducted efficiently. In this study, the factors affecting the recruitment and retention of participants enrolled
Sneha Amin, Irene Sangadi, Margaret Allman-Farinelli, Sunil V. Badve, Neil Boudville, Helen Coolican, Susan Coulshed, Sheryl Foster, Mangalee Fernando, Imad Haloob, David C.H. Harris, Carmel M. Hawley, Jane Holt, Martin Howell, Karthik Kumar, David W. Johnson, Vincent W. Lee, Jun Mai, Anna Rangan, Simon D. Roger, Kamal Sud, Vicente Torres, Eswari Vilayur, Gopala K. Rangan   +23 more
doaj  

p21 is decreased in polycystic kidney disease and leads to increased epithelial cell cycle progression: roscovitine augments p21 levels. [PDF]

, 2007
BackgroundAutosomal dominant polycystic kidney disease (ADPKD) is a common genetic disease with few treatment options other than renal replacement therapy. p21, a cyclin kinase inhibitor which has pleiotropic effects on the cell cycle, in many cases acts
Anderson, Sharon, Bagby, Susan P, Lindsley, Jessie N, Oyama, Terry T, Park, Jin-Young, Schutzer, William E, Weiss, Robert H   +6 more
core   +3 more sources

International consensus statement on the diagnosis and management of autosomal dominant polycystic kidney disease in children and young people

Nature Reviews Nephrology, 2019
These recommendations were systematically developed on behalf of the Network for Early Onset Cystic Kidney Disease (NEOCYST) by an international group of experts in autosomal dominant polycystic kidney disease (ADPKD) from paediatric and adult nephrology,
C. Gimpel, C. Bergmann, D. Bockenhauer, L. Breysem, M. Cadnapaphornchai, M. Cetiner, J. Dudley, F. Emma, M. Konrad, T. Harris, P. Harris, J. König, M. Liebau, M. Marlais, D. Mekahli, A. M. Metcalfe, J. Oh, R. Perrone, M. Sinha, A. Titieni, R. Torra, S. Weber, P. Winyard, F. Schaefer   +23 more
semanticscholar   +1 more source

Polycystic Kidney Disease [PDF]

Pediatrics In Review, 2009
1. Jacques Benun, MD 2. Carol Lewis, MD 1. Hasbro Children's Hospital Providence, RI Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD): The New Horizon For Children Who Have DPKD . Rizk D, Chapman A. Pediatr Nephrol. 2008;23 :1029– 1036[OpenUrl][1][CrossRef][2][PubMed][3] Autosomal Recessive Polycystic Kidney Disease ...
Carol Lewis, Jacques Benun
  +9 more sources

Improved Structure and Function in Autosomal Recessive Polycystic Rat Kidneys with Renal Tubular Cell Therapy. [PDF]

PLoS ONE, 2015
Autosomal recessive polycystic kidney disease is a truly catastrophic monogenetic disease, causing death and end stage renal disease in neonates and children.
K J Kelly, Jizhong Zhang, Ling Han, Malgorzata Kamocka, Caroline Miller, Vincent H Gattone, Jesus H Dominguez   +6 more
doaj   +1 more source

The emerging role of cellular senescence in renal diseases [PDF]

, 2020
Cellular senescence represents the state of irreversible cell cycle arrest during cell division. Cellular senescence not only plays a role in diverse biological events such as embryogenesis, tissue regeneration and repair, ageing and tumour occurrence ...
Alpini, Gianfranco, Chen, Rong, Francis, Heather, Glaser, Shannon, Li, Siwen, Li, Xuesen, Meng, Fanyin, Wan, Ying, Wu, Nan, Zhang, Chunmei, Zhou, Bingru, Zhou, Tianhao, Zou, Ping   +12 more
core   +1 more source

Discovery and preclinical evaluation of anti-miR-17 oligonucleotide RGLS4326 for the treatment of polycystic kidney disease

Nature Communications, 2019
Autosomal dominant polycystic kidney disease (ADPKD), caused by mutations in either PKD1 or PKD2 genes, is one of the most common human monogenetic disorders and the leading genetic cause of end-stage renal disease.
Edmund C. Lee, T. Valencia, C. Allerson, Annelie E Schairer, Andrea Flaten, Matanel Yheskel, Kara Kersjes, Jian Li, Sole Gatto, Mandeep Takhar, S. Lockton, A. Pavlícek, Michael Kim, Tiffany T Chu, Randy Soriano, Scott Davis, J. Androsavich, Salma Sarwary, Tate Owen, J. Kaplan, Kai-zhen Liu, G. Jang, S. Neben, Philip J. Bentley, T. Wright, V. Patel   +25 more
semanticscholar   +1 more source

Polycystic horseshoe kidney [PDF]

Medical Journal Armed Forces India, 2015
Polycystic kidney disease (PKD) is a hereditary disorder of autosomal dominant or recessive inheritance. Horseshoe kidney is a common renal fusion anomaly during embryogenesis. Combination of both PKD and horseshoe kidney is rare, with an incidence of one in 1,34,000–8,00,000 live births.1 Less than twenty cases have been reported till date in adults ...
Mahadev N. Honawad, Panduranga Chikkannaiah, Akshay Bali, Ranjit Kangle   +3 more
openaire   +3 more sources

Pkd2 dosage influences cellular repair responses following ischemia-reperfusion injury [PDF]

, 2009
Autosomal dominant polycystic kidney disease (ADPKD) results from mutations in either PKD1 or PKD2 and accounts for 10% of all patients on renal replacement therapy. The kidney disease phenotype is primarily characterized by cyst formation, but there are
Haylor, J.L., McDaid, J.P., Ong, A.C.M., Prasad, S., Tam, F.W.K.   +4 more
core   +2 more sources

Prevalence Estimates of Polycystic Kidney and Liver Disease by Population Sequencing.

Journal of the American Society of Nephrology, 2018
BACKGROUND Estimating the prevalence of autosomal dominant polycystic kidney disease (ADPKD) is challenging because of age-dependent penetrance and incomplete clinical ascertainment.
M. Lanktree, A. Haghighi, E. Guiard, Ioan-Andrei Iliuta, Xuewen Song, P. Harris, A. Paterson, Y. Pei   +7 more
semanticscholar   +1 more source